These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16737908)

  • 1. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
    Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
    Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
    Fu YS; Ro J; Reagan JW; Hall TL; Berek J
    Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
    Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G;
    Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.
    Dodson MK; Hartmann LC; Cliby WA; DeLacey KA; Keeney GL; Ritland SR; Su JQ; Podratz KC; Jenkins RB
    Cancer Res; 1993 Oct; 53(19):4456-60. PubMed ID: 8402612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
    Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
    Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Borderline malignant serous tumors of the ovary maintained on extracellular matrix: evidence for clonal evolution and invasive potential.
    Crickard K; Marinello MJ; Crickard U; Satchidanand SK; Yoonessi M; Caglar H
    Cancer Genet Cytogenet; 1986 Oct; 23(2):135-43. PubMed ID: 3756833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors.
    Helou K; Padilla-Nash H; Wangsa D; Karlsson E; Osterberg L; Karlsson P; Ried T; Knutsen T
    Cancer Genet Cytogenet; 2006 Oct; 170(1):1-8. PubMed ID: 16965948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67.
    Kohlberger PD; Kieback DG; Mian C; Wiener H; Kainz C; Gitsch G; Breitenecker G
    J Soc Gynecol Investig; 1997; 4(5):262-4. PubMed ID: 9360232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization.
    Wolf NG; Abdul-Karim FW; Farver C; Schröck E; du Manoir S; Schwartz S
    Genes Chromosomes Cancer; 1999 Aug; 25(4):307-15. PubMed ID: 10398423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.